AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,609,220 | +35.4% | 51,586 | +24.9% | 0.01% | +60.0% |
| Q2 2023 | $1,927,643 | +67.3% | 41,286 | +37.1% | 0.01% | +66.7% |
| Q1 2023 | $1,152,353 | -26.6% | 30,119 | +5.1% | 0.00% | -40.0% |
| Q4 2022 | $1,571,006 | +148.2% | 28,668 | +54.3% | 0.01% | +150.0% |
| Q3 2022 | $633,000 | +268.0% | 18,581 | +2.3% | 0.00% | – |
| Q2 2022 | $172,000 | -63.6% | 18,166 | -45.4% | 0.00% | -100.0% |
| Q1 2022 | $473,000 | -32.8% | 33,300 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $704,000 | -5.4% | 33,300 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $744,000 | -9.9% | 33,300 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $826,000 | +56.4% | 33,300 | +83.0% | 0.00% | +100.0% |
| Q1 2021 | $528,000 | +7.8% | 18,200 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $490,000 | +23.4% | 19,000 | +47.3% | 0.00% | 0.0% |
| Q3 2020 | $397,000 | +23.7% | 12,900 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $321,000 | +17.6% | 12,900 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $273,000 | – | 12,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 1,621,829 | $75,723,196 | 32.88% |
| COMMODORE CAPITAL LP | 1,675,000 | $78,205,750 | 8.79% |
| Ghost Tree Capital, LLC | 360,000 | $16,808,400 | 5.55% |
| Boxer Capital, LLC | 1,676,733 | $78,287 | 3.63% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 241,357 | $11,268,958 | 3.49% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $27,745,579 | 3.45% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 236,500 | $11,039,820 | 3.42% |
| Logos Global Management LP | 520,000 | $24,278,800 | 3.30% |
| Redmile Group, LLC | 1,811,672 | $84,586,966 | 3.25% |
| Yiheng Capital Management, L.P. | 1,201,591 | $56,102,284 | 3.03% |